

# Jonathan D Karnon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8722326/publications.pdf>

Version: 2024-02-01

176  
papers

4,319  
citations

172457

29  
h-index

133252

59  
g-index

179  
all docs

179  
docs citations

179  
times ranked

6052  
citing authors

#	ARTICLE	IF	CITATIONS
1	Model Parameter Estimation and Uncertainty Analysis. <i>Medical Decision Making</i> , 2012, 32, 722-732.	2.4	564
2	Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6. <i>Value in Health</i> , 2012, 15, 835-842.	0.3	478
3	Modeling Using Discrete Event Simulation. <i>Medical Decision Making</i> , 2012, 32, 701-711.	2.4	189
4	Modeling using Discrete Event Simulation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4. <i>Value in Health</i> , 2012, 15, 821-827.	0.3	166
5	Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System. <i>Pharmacoeconomics</i> , 2018, 36, 239-252.	3.3	153
6	A Randomized Trial of a 1-Hour Troponin T Protocol in Suspected Acute Coronary Syndromes. <i>Circulation</i> , 2019, 140, 1543-1556.	1.6	144
7	Calibrating Models in Economic Evaluation. <i>Pharmacoeconomics</i> , 2011, 29, 35-49.	3.3	123
8	Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation. <i>Health Economics (United Kingdom)</i> , 2003, 12, 837-848.	1.7	111
9	Identifying existing health care services that do not provide value for money. <i>Medical Journal of Australia</i> , 2009, 190, 269-273.	1.7	108
10	Model-based cost-effectiveness analysis of interventions aimed at preventing medication error at hospital admission (medicines reconciliation). <i>Journal of Evaluation in Clinical Practice</i> , 2009, 15, 299-306.	1.8	108
11	Process Mining for Clinical Processes. <i>ACM Transactions on Management Information Systems</i> , 2015, 5, 1-18.	2.8	101
12	Selecting a decision model for economic evaluation: a case study and review. <i>Health Care Management Science</i> , 1998, 1, 133-140.	2.6	62
13	Cost-Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Solid Tumors. <i>Journal of Clinical Oncology</i> , 2011, 29, 3270-3277.	1.6	60
14	Home Videophones Improve Direct Observation in Tuberculosis Treatment: A Mixed Methods Evaluation. <i>PLoS ONE</i> , 2012, 7, e50155.	2.5	59
15	Calibrating Models in Economic Evaluation. <i>Pharmacoeconomics</i> , 2011, 29, 51-62.	3.3	52
16	A Simple Decision Analysis of a Mandatory Lockdown Response to the COVID-19 Pandemic. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 329-331.	2.1	52
17	When to Use Discrete Event Simulation (DES) for the Economic Evaluation of Health Technologies? A Review and Critique of the Costs and Benefits of DES. <i>Pharmacoeconomics</i> , 2014, 32, 547-558.	3.3	51
18	Increasing trends in hospitalisations due to atrial fibrillation in Australia from 1993 to 2013. <i>Heart</i> , 2019, 105, 1358-1363.	2.9	51

#	ARTICLE	IF	CITATIONS
19	Modelling the Expected Net Benefits of Interventions to Reduce the Burden of Medication Errors. <i>Journal of Health Services Research and Policy</i> , 2008, 13, 85-91.	1.7	41
20	The Cost of Treating Advanced Non-Small Cell Lung Cancer: Estimates from the Chinese Experience. <i>PLoS ONE</i> , 2012, 7, e48323.	2.5	36
21	Cost Effectiveness of Extended Adjuvant Letrozole in Postmenopausal Women after Adjuvant Tamoxifen Therapy. <i>Pharmacoeconomics</i> , 2006, 24, 237-250.	3.3	35
22	Cost-utility analysis of screening high-risk groups for anal cancer. <i>Journal of Public Health</i> , 2008, 30, 293-304.	1.8	35
23	Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. <i>American Journal of Managed Care</i> , 2006, 12, 374-86.	1.1	34
24	Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective. <i>Breast Cancer Research and Treatment</i> , 2008, 108, 375-387.	2.5	33
25	Cost-effectiveness of using <i>CYP2C19</i> genotype to guide selection of clopidogrel or ticagrelor in Australia. <i>Pharmacogenomics</i> , 2013, 14, 2013-2021.	1.3	33
26	The implementation of ergonomics advice and the stage of change approach. <i>Applied Ergonomics</i> , 2015, 51, 370-376.	3.1	33
27	Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. <i>European Journal of Health Economics</i> , 2008, 9, 171-183.	2.8	31
28	Improving the Accuracy and Comparability of Model-Based Economic Evaluations of Health Technologies for Reimbursement Decisions. <i>Medical Decision Making</i> , 2013, 33, 325-332.	2.4	31
29	Effectiveness of earlier antenatal screening for sickle cell disease and thalassaemia in primary care: cluster randomised trial. <i>BMJ: British Medical Journal</i> , 2010, 341, c5132-c5132.	2.3	30
30	A Critical Review of Model-Based Economic Studies of Depression. <i>Pharmacoeconomics</i> , 2012, 30, 461-482.	3.3	28
31	Economic Evaluations in Rheumatoid Arthritis. <i>Pharmacoeconomics</i> , 2008, 26, 395-408.	3.3	27
32	Late Outcomes of the RAPID-TnT Randomized Controlled Trial: 0/1-Hour High-Sensitivity Troponin T Protocol in Suspected ACS. <i>Circulation</i> , 2021, 144, 113-125.	1.6	27
33	Increasing impacts of temperature on hospital admissions, length of stay, and related healthcare costs in the context of climate change in Adelaide, South Australia. <i>Science of the Total Environment</i> , 2021, 773, 145656.	8.0	25
34	Exploring Structural Uncertainty in Model-Based Economic Evaluations. <i>Pharmacoeconomics</i> , 2015, 33, 435-443.	3.3	24
35	Frailty and health service use in rural South Australia. <i>Archives of Gerontology and Geriatrics</i> , 2016, 62, 53-58.	3.0	24
36	Tamoxifen Plus Chemotherapy versus Tamoxifen Alone as Adjuvant Therapies for Node-Positive Postmenopausal Women with Early Breast Cancer. <i>Pharmacoeconomics</i> , 2002, 20, 119-137.	3.3	23

#	ARTICLE	IF	CITATIONS
37	Aromatase Inhibitors in Breast Cancer. <i>Pharmacoeconomics</i> , 2006, 24, 215-232.	3.3	23
38	A qualitative study of sustainability and vulnerability in Australian telehealth services. <i>Studies in Health Technology and Informatics</i> , 2010, 161, 190-201.	0.3	23
39	Planning the efficient allocation of research funds: an adapted application of a non-parametric Bayesian value of information analysis. <i>Health Policy</i> , 2002, 61, 329-347.	3.0	22
40	Screening for important unwarranted variation in clinical practice: a triple-test of processes of care, costs and patient outcomes. <i>Australian Health Review</i> , 2017, 41, 104.	1.1	22
41	A prospective hazard and improvement analytic approach to predicting the effectiveness of medication error interventions. <i>Safety Science</i> , 2007, 45, 523-539.	4.9	21
42	Informing disinvestment through cost-effectiveness modelling. <i>Applied Health Economics and Health Policy</i> , 2009, 7, 1-9.	2.1	21
43	Option B+ for the prevention of mother-to-child transmission of HIV infection in developing countries: a review of published cost-effectiveness analyses. <i>Health Policy and Planning</i> , 2016, 31, 1133-1141.	2.7	20
44	Determining Value in Health Technology Assessment: Stay the Course or Tack Away?. <i>Pharmacoeconomics</i> , 2019, 37, 293-299.	3.3	19
45	A Critique and Impact Analysis of Decision Modeling Assumptions. <i>Medical Decision Making</i> , 2007, 27, 491-499.	2.4	18
46	To teach or not to teach? A cost-benefit analysis of teaching in private general practice. <i>Medical Journal of Australia</i> , 2010, 193, 608-613.	1.7	18
47	Model Performance Evaluation (Validation and Calibration) in Model-based Studies of Therapeutic Interventions for Cardiovascular Diseases. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 85-93.	2.1	18
48	Practice nurse involvement in general practice clinical care: policy and funding issues need resolution. <i>Australian Health Review</i> , 2014, 38, 301.	1.1	18
49	Impact of heatwave intensity using excess heat factor on emergency department presentations and related healthcare costs in Adelaide, South Australia. <i>Science of the Total Environment</i> , 2021, 781, 146815.	8.0	18
50	A model for analyzing the cost of the main clinical events after lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2001, 20, 474-482.	0.6	17
51	What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia. <i>Cost Effectiveness and Resource Allocation</i> , 2016, 14, 11.	1.5	17
52	Cost effectiveness of high-sensitivity troponin compared to conventional troponin among patients presenting with undifferentiated chest pain: A trial based analysis. <i>International Journal of Cardiology</i> , 2017, 238, 144-150.	1.7	17
53	A Hybrid Cohort Individual Sampling Natural History Model of Age-Related Macular Degeneration: Assessing the Cost-Effectiveness of Screening Using Probabilistic Calibration. <i>Medical Decision Making</i> , 2009, 29, 304-316.	2.4	16
54	Addressing the Challenge for Well Informed and Consistent Reimbursement Decisions. <i>Pharmacoeconomics</i> , 2011, 29, 823-825.	3.3	16

#	ARTICLE	IF	CITATIONS
55	A proposed model for economic evaluations of major depressive disorder. <i>European Journal of Health Economics</i> , 2012, 13, 501-510.	2.8	16
56	Health State Utility Values for Cost-Effectiveness Models. <i>Pharmacoeconomics</i> , 2017, 35, 1-3.	3.3	16
57	The stage of change approach for implementing ergonomics advice – Translating research into practice. <i>Applied Ergonomics</i> , 2017, 59, 225-233.	3.1	16
58	Oil-based or water-based contrast for hysterosalpingography in infertile women: a cost-effective analysis of a randomized controlled trial. <i>Fertility and Sterility</i> , 2018, 110, 754-760.	1.0	16
59	Effectiveness of an Ambient Intelligent Geriatric Management system (AmbiGeM) to prevent falls in older people in hospitals: protocol for the AmbiGeM stepped wedge pragmatic trial. <i>Injury Prevention</i> , 2019, 25, 157-165.	2.4	16
60	Strategies for implementing shared decision making in elective surgery by health care practitioners: A systematic review. <i>Journal of Evaluation in Clinical Practice</i> , 2020, 26, 582-601.	1.8	16
61	Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates. <i>Pharmacoeconomics</i> , 2022, 40, 31-43.	3.3	16
62	Economic evaluation alongside-of-1 trials: getting closer to the margin. <i>Health Economics (United Kingdom)</i> , 2020, 40, 1079-1100.	1.7	15
63	Lifetime Cost-Utility Analyses of Deferasirox in Beta-Thalassaemia Patients with Chronic Iron Overload. <i>Clinical Drug Investigation</i> , 2012, 32, 805-815.	2.2	15
64	APPLYING RISK ADJUSTED COST-EFFECTIVENESS (RACE) ANALYSIS TO HOSPITALS: ESTIMATING THE COSTS AND CONSEQUENCES OF VARIATION IN CLINICAL PRACTICE. <i>Health Economics (United Kingdom)</i> , 2013, 22, 631-642.	1.7	15
65	Accounting for Costs, QALYs, and Capacity Constraints. <i>Medical Decision Making</i> , 2013, 33, 986-997.	2.4	15
66	Cost-Effectiveness of Noninvasive Central Blood Pressure Monitoring in the Diagnosis of Hypertension. <i>American Journal of Hypertension</i> , 2015, 28, 604-614.	2.0	15
67	Improving the planning of the GP workforce in Australia: a simulation model incorporating work transitions, health need and service usage. <i>Human Resources for Health</i> , 2016, 14, 13.	3.1	15
68	Effectiveness of preoperative medical consultations by internal medicine physicians: a systematic review. <i>BMJ Open</i> , 2017, 7, e018632.	1.9	15
69	Sociodemographic variations in the amount, duration and cost of potentially preventable hospitalisation for chronic conditions among Aboriginal and non-Aboriginal Australians: a period prevalence study of linked public hospital data. <i>BMJ Open</i> , 2017, 7, e017331.	1.9	15
70	Screening for sickle cell and thalassaemia in primary care: a cost-effectiveness study. <i>British Journal of General Practice</i> , 2011, 61, e620-e627.	1.4	14
71	Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for Reporting. <i>Value in Health</i> , 2020, 23, 388-396.	0.3	14
72	Extrapolation of Survival Curves Using Standard Parametric Models and Flexible Parametric Spline Models: Comparisons in Large Registry Cohorts with Advanced Cancer. <i>Medical Decision Making</i> , 2021, 41, 179-193.	2.4	14

#	ARTICLE	IF	CITATIONS
73	Cost analysis of a hospital-at-home initiative using discrete event simulation. <i>Journal of Health Services Research and Policy</i> , 2001, 6, 14-22.	1.7	13
74	Model Structuring for Economic Evaluations of New Health Technologies. <i>Pharmacoeconomics</i> , 2018, 36, 1309-1319.	3.3	13
75	Translating a health service intervention into a rural setting: lessons learned. <i>BMC Health Services Research</i> , 2016, 16, 62.	2.2	12
76	Variation in Clinical Practice: A Priority Setting Approach to the Staged Funding of Quality Improvement. <i>Applied Health Economics and Health Policy</i> , 2016, 14, 21-27.	2.1	12
77	Cost-effectiveness modelling of IVF in couples with unexplained infertility. <i>Reproductive BioMedicine Online</i> , 2018, 37, 555-563.	2.4	11
78	Structuring a conceptual model for cost-effectiveness analysis of frailty interventions. <i>PLoS ONE</i> , 2019, 14, e0222049.	2.5	11
79	How much emergency department use by vulnerable populations is potentially preventable?: A period prevalence study of linked public hospital data in South Australia. <i>BMJ Open</i> , 2019, 9, e022845.	1.9	11
80	Re-designing a rapid response system: effect on staff experiences and perceptions of rapid response team calls. <i>BMC Health Services Research</i> , 2020, 20, 480.	2.2	11
81	The Case for a Temporary COVID-19 Income Tax Levy Now, During the Crisis. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 335-337.	2.1	11
82	A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK. <i>International Journal of Cardiology</i> , 2010, 140, 315-322.	1.7	10
83	The LINKIN Health Census process: design and implementation. <i>BMC Health Services Research</i> , 2012, 12, 321.	2.2	10
84	Achieving Allocative Efficiency in Healthcare: Nice in Theory, not so NICE in Practice?. <i>Pharmacoeconomics</i> , 2014, 32, 315-318.	3.3	10
85	A Cost-Effectiveness Model for Frail Older Persons: Development and Application to a Physiotherapy-Based Intervention. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 635-645.	2.1	10
86	Cost-effectiveness in surgery: concepts of cost-utility analysis explained. <i>ANZ Journal of Surgery</i> , 2021, 91, 1717-1723.	0.7	10
87	Modelling the Future Clinical and Economic Burden of Antimicrobial Resistance: The Feasibility and Value of Models to Inform Policy. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 479-486.	2.1	10
88	DOES ONE SIZE FIT ALL? COST UTILITY ANALYSES OF ALTERNATIVE MAMMOGRAPHIC FOLLOW-UP SCHEDULES, BY RISK OF RECURRENCE. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 281-288.	0.5	9
89	Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme. <i>Australian Health Review</i> , 2017, 41, 1.	1.1	9
90	Randomised clinical trials in perinatal health care: a cost-effective investment. <i>Medical Journal of Australia</i> , 2017, 207, 289-293.	1.7	9

#	ARTICLE	IF	CITATIONS
91	Developing a Model of Care for Home Infusions of Natalizumab for People With Multiple Sclerosis. <i>Journal of Infusion Nursing</i> , 2019, 42, 289-296.	2.3	9
92	Blood pressure control in Australian general practice: analysis using general practice records of 1.2 million patients from the MedicineInsight database. <i>Journal of Hypertension</i> , 2021, 39, 1134-1142.	0.5	9
93	Effectiveness of the Wearable Sensor-based Ambient Intelligent Geriatric Management (AmblGeM) System in Preventing Falls in Older People in Hospitals. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2022, 77, 155-163.	3.6	9
94	Hospital healthcare costs attributable to heat and future estimations in the context of climate change in Perth, Western Australia. <i>Advances in Climate Change Research</i> , 2021, 12, 638-648.	5.1	9
95	Sugar consumption from beverages and the potential effects of a text-based information label. <i>Australian and New Zealand Journal of Public Health</i> , 2011, 35, 88-89.	1.8	8
96	A Patient-Level Calibration Framework for Evaluating Surveillance Strategies: A Case Study of Mammographic Follow-Up After Early Breast Cancer. <i>Value in Health</i> , 2014, 17, 669-678.	0.3	8
97	What will make a difference? Assessing the impact of policy and non-policy scenarios on estimations of the future GP workforce. <i>Human Resources for Health</i> , 2017, 15, 43.	3.1	8
98	Behavioral Economic Insights to Improve Medication Adherence in Adults with Chronic Conditions: A Scoping Review. <i>Patient</i> , 2019, 12, 571-592.	2.7	8
99	Evaluating the effects of variation in clinical practice: a risk adjusted cost-effectiveness (RAC-E) analysis of acute stroke services. <i>BMC Health Services Research</i> , 2012, 12, 266.	2.2	7
100	Cost-effectiveness evaluation of the 45-49 year old health check versus usual care in Australian general practice: A modelling study. <i>PLoS ONE</i> , 2018, 13, e0207110.	2.5	7
101	A scoping review of the economics of multidisciplinary teams in oncology care. <i>Journal of Cancer Policy</i> , 2020, 26, 100257.	1.4	7
102	Cost-effectiveness analysis of imaging surveillance in stage II and III extremity soft tissue sarcoma: an Australian perspective. <i>Cost Effectiveness and Resource Allocation</i> , 2020, 18, 5.	1.5	7
103	Is different better? Models of teaching and their influence on the net financial outcome for general practice teaching posts. <i>BMC Medical Education</i> , 2011, 11, 45.	2.4	6
104	Monitoring progress in the management of hip fractures in South Australia, Australia. <i>Archives of Osteoporosis</i> , 2012, 7, 267-273.	2.4	6
105	A Model-Based Economic Evaluation of Improved Primary Care Management of Patients with Type 2 Diabetes in Australia. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 661-670.	2.1	6
106	Implementation of interventions to prevent musculoskeletal injury at work – lost in translation?. <i>Physical Therapy Reviews</i> , 2013, 18, 344-349.	0.8	6
107	Managing high-risk surgical patients: modifiable comorbidities matter. <i>ANZ Journal of Surgery</i> , 2014, 84, 925-931.	0.7	6
108	Should the Lambda (λ) Remain Silent?. <i>Pharmacoeconomics</i> , 2016, 34, 323-329.	3.3	6

#	ARTICLE	IF	CITATIONS
109	A long-term evaluation of the stage of change approach and compensable injury outcomes – a cluster-randomised trial. <i>Ergonomics</i> , 2017, 60, 628-635.	2.1	6
110	Unconnected and out-of-sight: identifying health care non-users with unmet needs. <i>BMC Health Services Research</i> , 2017, 17, 80.	2.2	6
111	The long-term costs and effects of tubal flushing with oil-based versus water-based contrast during hysterosalpingography. <i>Reproductive BioMedicine Online</i> , 2021, 42, 150-157.	2.4	6
112	Pragmatic review of interventions to prevent inpatient hypoglycaemia. <i>Diabetic Medicine</i> , 2022, 39, e14737.	2.3	6
113	Are Estimates of the Health Opportunity Cost Being Used to Draw Conclusions in Published Cost-Effectiveness Analyses? A Scoping Review in Four Countries. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 337-349.	2.1	6
114	Practice nurse involvement in primary care depression management: an observational cost-effectiveness analysis. <i>BMC Family Practice</i> , 2014, 15, 10.	2.9	5
115	The never ending road: improving, adapting and refining a needs-based model to estimate future general practitioner requirements in two Australian states. <i>Family Practice</i> , 2018, 35, 193-198.	1.9	5
116	Health related quality of life (HRQoL) among Aboriginal South Australians: a perspective using survey-based health utility estimates. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 39.	2.4	5
117	Improving Decision-Making Processes in Health: Is It Time for (Disease-Specific) Reference Models?. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 1-4.	2.1	5
118	Mapping a decade of interventions to address the supportive care needs of individuals living with or beyond cancer: a scoping review of reviews. <i>Supportive Care in Cancer</i> , 2022, 30, 3793.	2.2	5
119	Evaluating cost benefits from a heat health warning system in Adelaide, South Australia. <i>Australian and New Zealand Journal of Public Health</i> , 2022, 46, 149-154.	1.8	5
120	Predicted cardiovascular disease risk and prescribing of antihypertensive therapy among patients with hypertension in Australia using MedicineInsight. <i>Journal of Human Hypertension</i> , 2023, 37, 370-378.	2.2	5
121	Developing a relativities approach to valuing the prevention of non-fatal work-related accidents and ill health. <i>Health Economics (United Kingdom)</i> , 2005, 14, 1103-1115.	1.7	4
122	Cost-effectiveness of letrozole, anastrozole and exemestane for early adjuvant breast cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2007, 7, 143-153.	1.4	4
123	Decision Modeling to Inform Decision Making: Seeing the Wood for the Trees. <i>Medical Decision Making</i> , 2010, 30, E20-E22.	2.4	4
124	The efficient price: an opportunity for funding reform. <i>Australian Health Review</i> , 2011, 35, 501.	1.1	4
125	Development and calibration of a constrained resource health outcomes simulation model of hospital-based glaucoma services. <i>Health Systems</i> , 2013, 2, 181-197.	1.2	4
126	Cost-Value Analysis and the SAVE: A Work in Progress, But an Option for Localised Decision Making?. <i>Pharmacoeconomics</i> , 2015, 33, 1281-1288.	3.3	4



#	ARTICLE	IF	CITATIONS
127	Model Validation: Has itâ€™s Time Come?. <i>Pharmacoeconomics</i> , 2016, 34, 829-831.	3.3	4
128	Is the Counterweight Program a feasible and acceptable option for structured weight management delivered by practice nurses in Australia? A mixed-methods study. <i>Australian Journal of Primary Health</i> , 2017, 23, 348.	0.9	4
129	The political economy of the assessment of value of new health technologies. <i>Journal of Health Services Research and Policy</i> , 2018, 23, 116-122.	1.7	4
130	What is multidisciplinary cancer care like in practice? a protocol for a mixed-method study to characterise ambulatory oncology services in the Australian public sector. <i>BMJ Open</i> , 2019, 9, e031179.	1.9	4
131	Economics of multidisciplinary teams in oncology. <i>JBI Evidence Synthesis</i> , 2019, Publish Ahead of Print, 1285-1291.	1.3	4
132	The representation of public values in health technology assessment to inform funding decisions: the case of Australia's national funding bodies. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e22.	0.5	4
133	Prioritising models of healthcare service delivery for a more sustainable health system: a Delphi study of Australian health policy, clinical practice and management, academic and consumer stakeholders. <i>Australian Health Review</i> , 2021, 45, 425.	1.1	4
134	An integrated knowledge translation approach to address avoidable rehospitalisations and unplanned admissions for older people in South Australia: implementation and evaluation program plan. <i>Implementation Science Communications</i> , 2021, 2, 36.	2.2	4
135	Home infusions of natalizumab for people with multiple sclerosis: a pilot randomised crossover trial. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1610-1621.	3.7	4
136	Improving cost-effectiveness of endoscopic surveillance for Barrettâ€™s esophagus by reducing low-value care: a review of economic evaluations. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 5905-5917.	2.4	4
137	A model-based evaluation of collaborative care in management of patients with type 2 diabetes in Australia: an initial report. <i>Australian Health Review</i> , 2012, 36, 258.	1.1	4
138	Itâ€™s Not the Model, Itâ€™s the Way You Use It: Exploratory Early Health Economics Amid Complexity Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modelling". <i>International Journal of Health Policy and Management</i> , 2021, 10, 36-38.	0.9	4
139	COST-UTILITY ANALYSIS OF PRIVATE CONTRACTING TO REDUCE PUBLIC WAITING TIMES FOR JOINT REPLACEMENT SURGERY. <i>International Journal of Technology Assessment in Health Care</i> , 2018, 34, 147-155.	0.5	3
140	Are the benefits of new health services greater than their opportunity costs?. <i>Australian Health Review</i> , 2019, 43, 508-510.	1.1	3
141	in-DEPtH framework: evidence-informed, co-creation framework for the Design, Evaluation and Procurement of Health services. <i>BMJ Open</i> , 2019, 9, e026482.	1.9	3
142	The Economic Value of the Delivery of Primary Cleft Surgery in Timor Leste 2000â€“2017. <i>World Journal of Surgery</i> , 2020, 44, 1699-1705.	1.6	3
143	Embedding an economist in regional and rural health services to add value and reduce waste by improving local-level decision-making: protocol for the â€˜embedded Economistâ€™ program and evaluation. <i>BMC Health Services Research</i> , 2021, 21, 201.	2.2	3
144	Expediting Patient Access to New Health Technologies: Role of Disease-Specific Reference Models. <i>Value in Health</i> , 2021, 24, 755-758.	0.3	3

#	ARTICLE	IF	CITATIONS
145	Cost effectiveness of a 1-hour high-sensitivity troponin-T protocol: An analysis of the RAPID-TnT trial. <i>IJC Heart and Vasculature</i> , 2022, 38, 100933.	1.1	3
146	An Observational Study to Assess the Effectiveness of 4CMenB against Meningococcal Disease and Carriage and Gonorrhoea in Adolescents in the Northern Territory, Australiaâ€”Study Protocol. <i>Vaccines</i> , 2022, 10, 309.	4.4	3
147	Understanding current and projected emergency department presentations and associated healthcare costs in a changing thermal climate in Adelaide, South Australia. <i>Occupational and Environmental Medicine</i> , 2022, 79, 421-426.	2.8	3
148	Using modelling in a phased approach to the economic evaluation of adjuvant therapy for early breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 1999, 32, 95-103.	4.4	2
149	Strategies for implementing shared decision making in elective surgery by healthcare practitioners: a systematic review protocol. <i>JB I Database of Systematic Reviews and Implementation Reports</i> , 2016, 14, 100-108.	1.7	2
150	A comparison of propensity scoreâ€”based approaches to health service evaluation: a case study of a preoperative physicianâ€”led clinic for highâ€”risk surgical patients. <i>Journal of Evaluation in Clinical Practice</i> , 2016, 22, 761-770.	1.8	2
151	Clinical indications treated with unregistered antimicrobials: regulatory challenges of antimicrobial resistance and access to effective treatment for patients. <i>Australian Health Review</i> , 2020, 44, 263.	1.1	2
152	Feasibility of de-linking reimbursement of antimicrobials from sales: the Australian perspective as a qualitative case study. <i>JAC-Antimicrobial Resistance</i> , 2020, 2, dlaa023.	2.1	2
153	Scoping review of Australian evaluations of healthcare delivery models: are we making the most of the evidence?. <i>Australian Health Review</i> , 2020, 44, 557-562.	1.1	2
154	Providing outpatient cancer care for CALD patients: a qualitative study. <i>BMC Research Notes</i> , 2021, 14, 304.	1.4	2
155	Access, Use, and Patient-Reported Experiences of Emergency Care During the COVID-19 Pandemic: Population-Based Survey. <i>JMIR Human Factors</i> , 2021, 8, e30878.	2.0	2
156	Heat-attributable hospitalisation costs in Sydney: Current estimations and future projections in the context of climate change. <i>Urban Climate</i> , 2021, 40, 101028.	5.7	2
157	Cost-effectiveness of letrozole in the treatment of advanced breast cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2004, 4, 383-391.	1.4	1
158	INFORMING DISINVESTMENT WITH LIMITED EVIDENCE: COBALAMIN DEFICIENCY IN THE FATIGUED. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 188-196.	0.5	1
159	Predictive Validation and the Re-Analysis of Cost-Effectiveness: Do We Dare to Tread?. <i>Pharmacoeconomics</i> , 2017, 35, 1111-1112.	3.3	1
160	Behavioral economic insights to improve medication adherence in adults with chronic conditions. <i>JB I Database of Systematic Reviews and Implementation Reports</i> , 2019, 17, 1915-1923.	1.7	1
161	Evaluations of healthcare delivery models in Australia. <i>JB I Database of Systematic Reviews and Implementation Reports</i> , 2020, 18, 128-134.	1.7	1
162	Models for delivery and co-ordination of primary or secondary health care (or both) to older adults living in aged care facilities. <i>The Cochrane Library</i> , 0, , .	2.8	1

#	ARTICLE	IF	CITATIONS
163	Characteristics of Quality Activities in a Tertiary Teaching Hospital in Western Australia. <i>International Journal for Quality in Health Care</i> , 2021, 33, .	1.8	1
164	Should Health Economic Evaluations Undertaken from a Societal Perspective Include Net Government Spending Multiplier Effects?. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 467-475.	2.1	1
165	Value assessment of antimicrobials and the implications for development, access, and funding of effective treatments: Australian stakeholder perspective. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e28.	0.5	1
166	Evaluation of collaborative models of care in the management of patients with depression: protocol and progress. <i>Mental Health in Family Medicine</i> , 2012, 9, 91-7.	0.2	1
167	Effect of a multi-faceted rapid response system re-design on repeat calling of the rapid response team. <i>PLoS ONE</i> , 2022, 17, e0265485.	2.5	1
168	Costs and uptake of a community model of paediatric food allergy care versus specialist hospital care: A before-and-after controlled trial. <i>Journal of Paediatrics and Child Health</i> , 2020, 56, 1225-1232.	0.8	0
169	Estimating the utilisation of unregistered antimicrobials in Australia. <i>Infection, Disease and Health</i> , 2020, 25, 82-91.	1.1	0
170	Peer-led HIV care and the UNAIDS 90-90-90 treatment targets in Tigray, Ethiopia: a cluster randomised trial and economic evaluation of <i>teach-test-link-trace</i> model (TTLT) trial protocol. <i>BMJ Open</i> , 2021, 11, e043943.	1.9	0
171	Understanding the Impacts of Temperature on Hospital Admissions, Length of Stay, and Related Healthcare Costs under the Changing Climate. <i>ISEE Conference Abstracts</i> , 2021, 2021, .	0.0	0
172	Healthcare Costs of Emergency Department Presentations Related to Heatwave Intensity and Severity. <i>ISEE Conference Abstracts</i> , 2021, 2021, .	0.0	0
173	Strategies for Avoiding Neglect of Opportunity Costs by Decision-Makers. <i>Applied Health Economics and Health Policy</i> , 2021, , 1.	2.1	0
174	Cost-effectiveness of programmed cell death protein 1/programmed death-ligand 1 inhibitors (aPD1/aPDL1) varies widely.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18351-e18351.	1.6	0
175	The complexities, coordination, culture and capacities that characterise the delivery of oncology services in the common areas of ambulatory settings. <i>BMC Health Services Research</i> , 2022, 22, 190.	2.2	0
176	Delivery of intravenous anti-cancer therapy at home versus in hospital or community settings for adults with cancer. <i>The Cochrane Library</i> , 2022, 2022, .	2.8	0